We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
A University of Cambridge analysis showed vaccination would prevent seven intensive-care admissions over a four-month period if new daily cases were detected at 200 per 100,000 people, and that it would prevent 0.8 admissions if daily cases were 20 per 100,000. "Can the AstraZeneca Vaccine Cause Blood Clots? What You Need to Know," at 10:46 ET, incorrectly said seven and 0.8 admissions would be expected per 100,000 people over the four-month period, and misstated the ratio of cases in the second example as 0.2 per 100,000.
(END) Dow Jones Newswires
April 08, 2021 13:46 ET (17:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions